外照射放疗或近距离放疗联合或不联合短期新辅助雄激素剥夺治疗的生活质量多中心前瞻性研究
该多中心前瞻性研究分析了早期前列腺癌患者接受放疗联合或不联合新辅助雄激素剥夺治疗(NADT)后2年的健康相关生活质量(HRQOL)。结果显示,外照射放疗(EBRT)联合NADT组在达到性高潮能力、勃起质量和性功能方面较基线恶化的比例显著高于单纯EBRT组,但勃起能力、勃起频率、整体性功能、潮热、乳房压痛/增大、抑郁、乏力或体重变化无差异。作者建议对中高危患者进行NADT和EBRT的HRQOL影响预处理咨询。
要点
- EBRT联合NADT组2年内达到性高潮能力、勃起质量和性功能恶化比例显著高于单纯EBRT组。
- 两组在勃起能力、勃起频率、整体性功能、潮热、乳房症状、抑郁、乏力和体重变化方面无显著差异。
- 中高危患者接受NADT联合EBRT生存获益,需预处理咨询HRQOL影响。
核心结论
- 与基线相比,2年时接受NADT联合EBRT的参与者相比单纯EBRT参与者,在达到性高潮能力、勃起质量和性功能方面HRQOL更差。
研究设计与样本
- 多中心前瞻性队列研究,分析前列腺癌治疗质量评估与满意度联盟的纵向数据,纳入新诊断早期前列腺癌接受EBRT或近距离放疗联合或不联合NADT的男性。
主要发现
- EBRT联合NADT组达到性高潮能力、勃起质量和性功能从基线到24个月恶化的比例分别为24%、23%和30%,单纯EBRT组分别为14%、13%和16%。
关键数值与推荐
- HRQOL采用扩展前列腺癌指数综合26项问卷在NADT开始后2、6、12和24个月测量。
- 组间百分比变化比较使用χ2或Fisher精确检验,双侧5%显著性水平。
临床怎么用
- 对接受NADT联合EBRT的中高危前列腺癌患者,治疗前应咨询NADT对HRQOL(尤其是性功能)的潜在影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The long-term effects of neoadjuvant androgen deprivation therapy (NADT) with radiation therapy on participant-reported health-related quality of life (HRQOL) have not been characterized in prospective multicenter studies. We evaluated HRQOL for 2 years among participants undergoing radiation therapy (RT) with or without NADT for newly diagnosed, early-stage prostate cancer. METHODS AND MATERIALS: We analyzed longitudinal cohort data from the Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium to ascertain the HRQOL trajectory of men receiving NADT with external beam RT (EBRT) or brachytherapy. HRQOL was measured using the expanded prostate cancer index composite 26-item questionnaire at 2, 6, 12, and 24 months after the initiation of NADT. We used the χ2 or Fisher exact test to compare the shift in percentages between groups that did or did not receive NADT. Analyses were conducted at the 2-sided 5% significance level. RESULTS: For subjects receiving EBRT, questions regarding the ability to have an erection, ability to reach an orgasm, quality of erections, frequency of erections, ability to function sexually, and lack of energy were in a significantly worse dichotomized category for the patients receiving NADT. Comparing the baseline versus 24-month outcomes, 24%, 23%, and 30% of participants receiving EBRT plus NADT shifted to the worse dichotomized category for the ability to reach an orgasm, quality of erections, and ability to function sexually compared with 14%, 13%, and 16% in the EBRT group, respectively. CONCLUSIONS: Compared with baseline, at 2 years, participants receiving NADT plus EBRT compared with EBRT alone had worse HRQOL, as measured by the ability to reach orgasm, quality of erections, and ability to function sexually. However, no difference was found in the ability to have an erection, frequency of erections, overall sexual function, hot flashes, breast tenderness/enlargement, depression, lack of energy, or change in body weight. The improved survival in intermediate- and high-risk patients receiving NADT and EBRT necessitates pretreatment counseling of the HRQOL effect of NADT and EBRT.
引用
- Gay HA, Sanda MG, Liu J, et al. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. Int J Radiat Oncol Biol Phys. 2017. PMID: 28463150. doi:10.1016/j.ijrobp.2017.02.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。